AIM: To evaluate the risk of recurrence of hepatocellular cancer (HCC) after liver transplantation (LT). METHODS: The clinical records of 104 patients with HCC in the explanted liver were examined. RESULTS: HCC recurrence occurred in 12 patients. Recurrence was observed in all patients with a single nodule greater than 5 cm. Among the 5 patients with more than 3 tumours with a maximum diameter of 4.5 cm, no recurrence occurred. The survival rates were 81% and 64% at 1 and 5 years, respectively; the recurrence-free survival at 1 and 5 years was, respectively, 93% and 82%. Pre-LT alpha-fetoprotein (AFP) increased at a greater magnitude in patients who experienced recurrence, compared to those who did not. Tumour diameter, differentiation, satellitosis, AFP and the magnitude of AFP increase were predictive of recurrence. The 1- and 5-year recurrence-free survival for the 68 patients who had a single nodule up to 5 cm, or up to 3 nodules all less than 4.5 cm and with a maximum cumulative diameter of 8 cm, or more than 3 nodules all less than 2.5 cm, were 95% and 92%, respectively. For the 13 patients not meeting these criteria, the 1- and 5-year recurrence-free survival was, respectively, 75% and 54% (log Rank test p=0.019). CONCLUSIONS: Patients with more than 3 small HCC nodules before LT could still have a good outcome without recurrence. A rapid increase in AFP could be useful in identifying patients with a greater risk of post-LT HCC recurrence.
AIM: To evaluate the risk of recurrence of hepatocellular cancer (HCC) after liver transplantation (LT). METHODS: The clinical records of 104 patients with HCC in the explanted liver were examined. RESULTS: HCC recurrence occurred in 12 patients. Recurrence was observed in all patients with a single nodule greater than 5 cm. Among the 5 patients with more than 3 tumours with a maximum diameter of 4.5 cm, no recurrence occurred. The survival rates were 81% and 64% at 1 and 5 years, respectively; the recurrence-free survival at 1 and 5 years was, respectively, 93% and 82%. Pre-LT alpha-fetoprotein (AFP) increased at a greater magnitude in patients who experienced recurrence, compared to those who did not. Tumour diameter, differentiation, satellitosis, AFP and the magnitude of AFP increase were predictive of recurrence. The 1- and 5-year recurrence-free survival for the 68 patients who had a single nodule up to 5 cm, or up to 3 nodules all less than 4.5 cm and with a maximum cumulative diameter of 8 cm, or more than 3 nodules all less than 2.5 cm, were 95% and 92%, respectively. For the 13 patients not meeting these criteria, the 1- and 5-year recurrence-free survival was, respectively, 75% and 54% (log Rank test p=0.019). CONCLUSIONS:Patients with more than 3 small HCC nodules before LT could still have a good outcome without recurrence. A rapid increase in AFP could be useful in identifying patients with a greater risk of post-LT HCC recurrence.
Authors: Donal B O'Connor; John P Burke; John Hegarty; Aiden P McCormick; Niamh Nolan; Emir Hoti; Donal Maguire; Justin Geoghegan; Oscar Traynor Journal: World J Transplant Date: 2016-06-24
Authors: Hazem Mohamed Zakaria; Ahmed N Sallam; Islam I Ayoub; Sherif M Saleh; Doha Maher; Hazem Omar; Mohamed Abou-Shady; Ibrahim A Salama; El-Sayed A Soliman; Khaled Abou El-Ella; Tarek M Ibrahim; Essam M Hammad Journal: Indian J Surg Date: 2016-04-07 Impact factor: 0.656
Authors: Christine Koch; Theresa Bette; Oliver Waidmann; Natalie Filmann; Christopher Schrecker; Jörg Trojan; Nina Weiler; Johannes Vermehren; Andreas A Schnitzbauer; Wolf Otto Bechstein; Stefan Zeuzem; Eva Herrmann; Martin-Walter Welker Journal: PLoS One Date: 2020-07-02 Impact factor: 3.240
Authors: Xin Zheng; Natalia B Rumie Vittar; Xiaohong Gai; Maite G Fernandez-Barrena; Catherine D Moser; Chunling Hu; Luciana L Almada; Angela L McCleary-Wheeler; Sherine F Elsawa; Anne M Vrabel; Abdirashid M Shire; Andrea Comba; Snorri S Thorgeirsson; Youngsoo Kim; Qingguang Liu; Martin E Fernandez-Zapico; Lewis R Roberts Journal: PLoS One Date: 2012-11-19 Impact factor: 3.240